Tarsus Pharmaceuticals, Inc. (TARS) Stock Overview
Explore Tarsus Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Tarsus Pharmaceuticals, Inc. (TARS)
Key Financials
Key Financials
Market Cap
3.9B
P/E Ratio
-82.35
EPS (TTM)
$-1.09
ROE
-0.14%
TARS Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Tarsus Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of TARS on the NASDAQ shows an RSI of 84.56, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $87.96 for the NASDAQ listing.
Key metrics behind Tarsus Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -82.35 and a market capitalization of 3.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TARS on the NASDAQ.